Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
3.880
-0.010 (-0.26%)
Jul 23, 2025, 12:53 PM - Market open
Lexeo Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Lexeo Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $16.6, which forecasts a 327.84% increase in the stock price over the next year. The lowest target is $10 and the highest is $20.
Price Target: $16.6 (+327.84%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 30, 2025.
Analyst Ratings
The average analyst rating for Lexeo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $16 → $10 | Buy | Maintains | $16 → $10 | +157.73% | May 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $23 → $15 | Strong Buy | Maintains | $23 → $15 | +286.60% | May 16, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $22 → $20 | Strong Buy | Maintains | $22 → $20 | +415.46% | May 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +492.78% | Apr 8, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +467.01% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.69
from -3.09
EPS Next Year
-2.06
from -2.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 59.9M | ||
| Avg | n/a | n/a | 19.4M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.71 | -1.20 | -0.98 | ||
| Avg | -2.69 | -2.06 | -2.04 | ||
| Low | -3.11 | -2.58 | -2.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.